Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 15.70 NOK
Change Today -0.30 / -1.87%
Volume 19.3K
As of 10:25 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

nattopharma asa (NATTO) Snapshot

Open
16.00 NOK
Previous Close
16.00 NOK
Day High
16.10 NOK
Day Low
15.50 NOK
52 Week High
07/2/14 - 22.09 NOK
52 Week Low
10/13/14 - 9.33 NOK
Market Cap
241.2M
Average Volume 10 Days
40.3K
EPS TTM
-1.61 NOK
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NATTOPHARMA ASA (NATTO)

Related News

No related news articles were found.

nattopharma asa (NATTO) Related Businessweek News

No Related Businessweek News Found

nattopharma asa (NATTO) Details

NattoPharma ASA produces nutrition supplements. It offers MenaQ7 that provides natural vitamin K2 (Menaquinone-7) as a fermentation extract for use in dietary supplements, and functional and fortified foods. The company sells its products through retail pharmacies. NattoPharma ASA was founded in 2004 and is based in Høvik, Norway.

10 Employees
Last Reported Date: 04/13/15
Founded in 2004

nattopharma asa (NATTO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nattopharma asa (NATTO) Key Developments

NattoPharma ASA's MenaQ7 PURE Obtains Novel Food Approval from EFSA

NattoPharma ASA has received written information from the Policy officer in the European Commission, DG Health and Food Safety, communicating that MenaQ7 PURE has received Novel Food approval by EFSA. As per the date of the NattoPharma Prospectus, April 10th 2015, such approval was not received. The MenaQ7 PURE product is a high quality product with efficient production costs. In combination with high quality this product is a good option for customers requiring low cost products, either by introducing MenaQ7 into existing products or by developing new product lines. NattoPharma considers that the potential for growth and increased revenues are within the synthetic products market within these segments, requiring huge volumes of MenaQ7 material.

NattoPharma ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

NattoPharma ASA reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported sales revenue of NOK 10.7 million against NOK 4.9 million a year ago. LBITDA was NOK 3.7 million against NOK 1.6 million a year ago. Net loss was NOK 3.2 million or NOK 0.35 per diluted share against profit of NOK 9.9 million or NOK 2.94 per diluted share a year ago. Operating loss was NOK 5.2 million compared to NOK 2.2 million for the same period of 2013. Loss before income tax was NOK 3,379,000 against profit of NOK 9,821,000 a year ago. For the year, the company reported sales revenue of NOK 25.5 million against NOK 16.4 million a year ago. LBITDA was NOK 18.5 million against NOK 10.0 million a year ago. Net loss was NOK 21.2 million or NOK 2.49 per diluted share against profit of NOK 0.4 million or NOK 4.79 per diluted share a year ago. Operating loss was NOK 24 million compared with a loss of NOK 10.9 million for the same period in 2013. Loss before income tax was NOK 21,851,000 against profit of NOK 387,000 a year ago. Negative net cash flow from operation activities was NOK 24,971,000 against NOK 17,536,000 a year ago. Purchases of property, plant and equipment were NOK 779,000.

NattoPharma ASA and Hofseth BioCare ASA Launch OmeGo and MenaQ7®

NattoPharma ASA (NP) and Hofseth BioCare ASA (HBC) have since 2014 collaborated to develop a product, combining Hofseth Biocare's OmeGoTM brand oil from salmon and NattoPharma's MenaQ7 brand Vitamin K2 ingredient. OmeGoTM is proven to be a superior co-active and carrier oil for Vitamin K2. The product will be launched at Natural Products Expo West in Anaheim, on March 5, 2015. Research and development of the combination product OmegoTM and MenaQ7® started in 2014. Product development has validated OmegoTM as a stable, bioactive companion oil for MenaQ7®. The OmegoTM oil is natively rich in properly ratio-balanced Essential Fatty Acids, includes long chain Omega 3 and is documented in human studies to modulate oxidized LDL cholesterol in a favorable way. MenaQ7® is documented to inhibit development of and even reverse existing arterial stiffness in a healthy population.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NATTO:NO 15.70 NOK -0.30

NATTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NATTO.
View Industry Companies
 

Industry Analysis

NATTO

Industry Average

Valuation NATTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATTOPHARMA ASA, please visit www.nattopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.